Literature DB >> 31102443

Analytical Treatment Interruptions and Human Immunodeficiency Virus Cure Research: Seizing the Opportunity While Maintaining Safety and Respect.

W David Hardy1.   

Abstract

Keywords:  HIV cure; analytical treatment interruption (ATI); risk-benefit; test-of-cure

Mesh：

Substances：

Year:  2020        PMID： 31102443     DOI： 10.1093/cid/ciz421

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  3 in total

1.  Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.

Authors:  Karen L Diepstra; Liz Barr; David Palm; Evelyn Hogg; Katie R Mollan; Laney Henley; Angela M Stover; Jane M Simoni; Jeremy Sugarman; Brandon Brown; John A Sauceda; Steven Deeks; Lawrence Fox; Rajesh T Gandhi; Davey Smith; Jonathan Z Li; Karine Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2021-02-16       Impact factor: 1.723

2.  Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research.

Authors:  Karine Dubé; John Kanazawa; Lynda Dee; Jeff Taylor; Danielle M Campbell; Brandon Brown; Mallory O Johnson; Parya Saberi; John A Sauceda; Jeremy Sugarman; Michael J Peluso
Journal:  HIV Res Clin Pract       Date:  2021-03-24

3.  Ethical and practical considerations for interventional HIV cure-related research at the end-of-life: A qualitative study with key stakeholders in the United States.

Authors:  John Kanazawa; Sara Gianella; Susanna Concha-Garcia; Jeff Taylor; Andy Kaytes; Christopher Christensen; Hursch Patel; Samuel Ndukwe; Stephen Rawlings; Steven Hendrickx; Susan Little; Brandon Brown; Davey Smith; Karine Dubé
Journal:  PLoS One       Date:  2021-07-16       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.